{"id":217695,"date":"2026-08-25T11:54:17","date_gmt":"2026-08-25T06:24:17","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=217695"},"modified":"2026-08-25T11:54:18","modified_gmt":"2026-08-25T06:24:18","slug":"biocon-share-price-japan-mhlw-pegfilgrastim-biosimilar-august-2026","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/biocon-share-price-japan-mhlw-pegfilgrastim-biosimilar-august-2026\/","title":{"rendered":"Biocon Share Price in Focus After Biocon Biologics Receives Japan MHLW Marketing Approval for Pegfilgrastim Biosimilar"},"content":{"rendered":"<div class=\"meta-block\"><\/div>\n<p style=\"border-left: 4px solid #1F4E79; background: #EBF3FB; padding: 10px 16px; font-style: italic;\"><em>BIOCON: Rs 409.40 (prev close). Biocon Biologics receives marketing approval for Pegfilgrastim biosimilar from Japan MHLW. Sandoz KK to promote\/sell in Japan. Aug 25, 2026.<\/em><\/p>\n<div style=\"background: #F0F9FF; border-left: 4px solid #2E7D32; border-radius: 6px; padding: 14px 18px; margin: 18px 0;\">\n<p style=\"margin: 0; color: #1f4e79; font-size: 14px;\"><strong>Quick Answer<\/strong><\/p>\n<p style=\"margin: 8px 0 0;\">Biocon Biologics, a wholly owned subsidiary of Biocon, received marketing approval for its Pegfilgrastim biosimilar from Japan&#8217;s Ministry of Health, Labour and Welfare (MHLW). The product, a biosimilar to Neulasta, is developed and manufactured by Biocon Biologics Ltd, the parent entity of Biocon Biologics UK PLC. Global Regulatory Partners Japan serves as the Marketing Authorization Holder on behalf of Biocon. Sandoz K.K. will exclusively promote, sell, and distribute the product in Japan. Biocon share price closed at Rs 409.40 in the previous session.<\/p>\n<\/div>\n<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_65 counter-hierarchy ez-toc-counter ez-toc-grey ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title \" >Table of Contents<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/univest.in\/blogs-2\/biocon-share-price-japan-mhlw-pegfilgrastim-biosimilar-august-2026\/#Biocon_Gets_Japan_MHLW_Approval_for_Pegfilgrastim_Biosimilar\" title=\"Biocon Gets Japan MHLW Approval for Pegfilgrastim Biosimilar\">Biocon Gets Japan MHLW Approval for Pegfilgrastim Biosimilar<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/univest.in\/blogs-2\/biocon-share-price-japan-mhlw-pegfilgrastim-biosimilar-august-2026\/#Biocon_Pegfilgrastim_Japan_Approval_Key_Details\" title=\"Biocon Pegfilgrastim Japan Approval: Key Details\">Biocon Pegfilgrastim Japan Approval: Key Details<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/univest.in\/blogs-2\/biocon-share-price-japan-mhlw-pegfilgrastim-biosimilar-august-2026\/#Why_the_Japan_MHLW_Approval_Is_Important_for_Biocon\" title=\"Why the Japan MHLW Approval Is Important for Biocon\">Why the Japan MHLW Approval Is Important for Biocon<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/univest.in\/blogs-2\/biocon-share-price-japan-mhlw-pegfilgrastim-biosimilar-august-2026\/#Biocon_Share_Price_Context_About_Biocon_and_Biocon_Biologics\" title=\"Biocon Share Price Context: About Biocon and Biocon Biologics\">Biocon Share Price Context: About Biocon and Biocon Biologics<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/univest.in\/blogs-2\/biocon-share-price-japan-mhlw-pegfilgrastim-biosimilar-august-2026\/#Biocon_Share_Price_Conclusion\" title=\"Biocon Share Price: Conclusion\">Biocon Share Price: Conclusion<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/univest.in\/blogs-2\/biocon-share-price-japan-mhlw-pegfilgrastim-biosimilar-august-2026\/#Frequently_Asked_Questions\" title=\"Frequently Asked Questions\">Frequently Asked Questions<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/univest.in\/blogs-2\/biocon-share-price-japan-mhlw-pegfilgrastim-biosimilar-august-2026\/#What_is_the_Biocon_Japan_MHLW_approval\" title=\"What is the Biocon Japan MHLW approval?\">What is the Biocon Japan MHLW approval?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/univest.in\/blogs-2\/biocon-share-price-japan-mhlw-pegfilgrastim-biosimilar-august-2026\/#What_is_Biocon_share_price_today\" title=\"What is Biocon share price today?\">What is Biocon share price today?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/univest.in\/blogs-2\/biocon-share-price-japan-mhlw-pegfilgrastim-biosimilar-august-2026\/#What_is_Pegfilgrastim_used_for\" title=\"What is Pegfilgrastim used for?\">What is Pegfilgrastim used for?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/univest.in\/blogs-2\/biocon-share-price-japan-mhlw-pegfilgrastim-biosimilar-august-2026\/#Who_will_sell_Biocons_Pegfilgrastim_in_Japan\" title=\"Who will sell Biocon&#8217;s Pegfilgrastim in Japan?\">Who will sell Biocon&#8217;s Pegfilgrastim in Japan?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/univest.in\/blogs-2\/biocon-share-price-japan-mhlw-pegfilgrastim-biosimilar-august-2026\/#Why_is_Japan_MHLW_approval_significant_for_Biocon\" title=\"Why is Japan MHLW approval significant for Biocon?\">Why is Japan MHLW approval significant for Biocon?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/univest.in\/blogs-2\/biocon-share-price-japan-mhlw-pegfilgrastim-biosimilar-august-2026\/#What_is_Biocon_Biologics_biosimilar_portfolio\" title=\"What is Biocon Biologics&#8217; biosimilar portfolio?\">What is Biocon Biologics&#8217; biosimilar portfolio?<\/a><\/li><\/ul><\/li><\/ul><\/nav><\/div>\n<h2><span class=\"ez-toc-section\" id=\"Biocon_Gets_Japan_MHLW_Approval_for_Pegfilgrastim_Biosimilar\"><\/span><strong>Biocon Gets Japan MHLW Approval for Pegfilgrastim Biosimilar<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p><a href=\"https:\/\/univest.in\/stocks\/biocon\/biocon-ltd-share-price-today\">Biocon<\/a> Biologics, the biosimilar arm of Biocon Ltd, has received marketing approval from Japan&#8217;s Ministry of Health, Labour and Welfare (MHLW) for its Pegfilgrastim biosimilar. Pegfilgrastim is a biologic drug used to prevent infections during chemotherapy by stimulating white blood cell production. The biosimilar is a reference to Neulasta, the original branded Pegfilgrastim marketed by Amgen. Biocon Biologics developed and manufactured the biosimilar, with Global Regulatory Partners Japan acting as the Marketing Authorization Holder in Japan, and Sandoz K.K. (Novartis subsidiary in Japan) as the exclusive commercial partner for promotion, sales, and distribution in Japan.<\/p>\n<p>The Biocon share price was Rs 409.40 in the prior session. Biocon share price had an intraday range of Rs 409 to Rs 414.55. The Japan MHLW approval adds Japan to Biocon Biologics&#8217; Pegfilgrastim regulatory portfolio, which already spans multiple global markets.<\/p>\n<p style=\"margin-top: 24px;\"><a href=\"https:\/\/univest.in\/user\/log-in?utm_source=blogs&amp;utm_medium=biocon-japan-mhlw-aug25\"><strong>Click Here and Get Free Investment Predictions<\/strong><\/a><\/p>\n<h2><span class=\"ez-toc-section\" id=\"Biocon_Pegfilgrastim_Japan_Approval_Key_Details\"><\/span><strong>Biocon Pegfilgrastim Japan Approval: Key Details<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<table style=\"border-collapse: collapse; width: 100%;\" border=\"1\" cellspacing=\"0\" cellpadding=\"6\">\n<tbody>\n<tr style=\"background: #1F4E79; color: #ffffff;\">\n<th>Parameter<\/th>\n<th>Detail<\/th>\n<\/tr>\n<tr>\n<td>Product<\/td>\n<td>Pegfilgrastim biosimilar (reference: Neulasta)<\/td>\n<\/tr>\n<tr>\n<td>Regulator<\/td>\n<td>Japan Ministry of Health, Labour and Welfare (MHLW)<\/td>\n<\/tr>\n<tr>\n<td>Developer and Manufacturer<\/td>\n<td>Biocon Biologics Ltd (parent entity of Biocon Biologics UK PLC)<\/td>\n<\/tr>\n<tr>\n<td>Marketing Authorization Holder<\/td>\n<td>Global Regulatory Partners Japan<\/td>\n<\/tr>\n<tr>\n<td>Commercial Partner in Japan<\/td>\n<td>Sandoz K.K. (exclusive promotion, sales, distribution)<\/td>\n<\/tr>\n<tr>\n<td>Biocon CMP (prev close)<\/td>\n<td>Rs 409.40<\/td>\n<\/tr>\n<tr>\n<td>Intraday Range (Aug 24)<\/td>\n<td>Rs 409 to Rs 414.55<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h2><span class=\"ez-toc-section\" id=\"Why_the_Japan_MHLW_Approval_Is_Important_for_Biocon\"><\/span><strong>Why the Japan MHLW Approval Is Important for Biocon<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Japan is the world&#8217;s third largest pharmaceutical market by value and has historically been one of the more challenging markets for biosimilar approvals due to strict regulatory standards and physician prescribing conservatism. Securing MHLW approval is therefore a significant regulatory milestone for Biocon Biologics. The partnership with Sandoz K.K. (the generics and biosimilars subsidiary of Novartis) is an ideal commercialisation channel in Japan given Sandoz&#8217;s established regulatory relationships, oncology market access, and distribution infrastructure.<\/p>\n<p>Pegfilgrastim is a high-value biologic used in cancer supportive care across all major global markets. Its entry into Japan through this approval adds to Biocon Biologics&#8217; revenue diversification and demonstrates the company&#8217;s ability to navigate complex regulatory environments beyond its established US and Europe presence in the <a href=\"https:\/\/univest.in\/indices\/nifty-pharma\/nifty-pharma-share-price-today\">Nifty Pharma<\/a> sector.<\/p>\n<p style=\"margin-top: 24px;\"><a href=\"https:\/\/univest.in\/screeners\"><strong>Screen Biocon on Univest Screener for Fundamentals and Regulatory Track Record<\/strong><\/a><\/p>\n<h2><span class=\"ez-toc-section\" id=\"Biocon_Share_Price_Context_About_Biocon_and_Biocon_Biologics\"><\/span><strong>Biocon Share Price Context: About Biocon and Biocon Biologics<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Biocon share price reflects one of India&#8217;s largest biotechnology companies, with Biocon Biologics as its biosimilar-focused subsidiary. Biocon Biologics has a global portfolio of biosimilars covering oncology support care (Pegfilgrastim, G-CSF), diabetes (insulin glargine, insulin aspart), immunology (Adalimumab, Trastuzumab), and ophthalmology (Bevacizumab) segments. The company is one of the largest biosimilar companies in the world by number of approved products across regulated markets.<\/p>\n<p style=\"margin-top: 24px;\"><em>Download the <a href=\"http:\/\/apps.apple.com\/in\/app\/univest-stocks-investment\/id6443753518\" rel=\"nofollow noopener\" target=\"_blank\">Univest iOS App<\/a> or <a href=\"http:\/\/play.google.com\/store\/apps\/details?id=com.univest.capp&amp;hl=en_IN\" rel=\"nofollow noopener\" target=\"_blank\">Univest Android App<\/a> to track Biocon share price and global regulatory approval updates live.<\/em><\/p>\n<h2><span class=\"ez-toc-section\" id=\"Biocon_Share_Price_Conclusion\"><\/span><strong>Biocon Share Price: Conclusion<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Biocon share price is in focus after Biocon Biologics received marketing approval for its Pegfilgrastim biosimilar from Japan&#8217;s MHLW. Sandoz K.K. will exclusively sell the product in Japan, adding the world&#8217;s third largest pharmaceutical market to Biocon Biologics&#8217; Pegfilgrastim commercial footprint. Biocon share price was Rs 409.40 in the previous session. Verify all data on NSE and BSE before making any investment decisions.<\/p>\n<div style=\"background: #CC0000; border-radius: 8px; padding: 16px 20px; margin: 24px 0;\">\n<p style=\"color: #ffffff; font-size: 13px; line-height: 1.7; margin: 0;\"><strong style=\"color: #ffffff;\">Disclaimer:<\/strong> Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).<\/p>\n<\/div>\n<h2><span class=\"ez-toc-section\" id=\"Frequently_Asked_Questions\"><\/span><strong>Frequently Asked Questions<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"What_is_the_Biocon_Japan_MHLW_approval\"><\/span><strong>What is the Biocon Japan MHLW approval?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Biocon Biologics received marketing approval from Japan&#8217;s Ministry of Health, Labour and Welfare (MHLW) for its Pegfilgrastim biosimilar. The product is a biosimilar to Neulasta (Amgen) developed and manufactured by Biocon Biologics. Sandoz K.K. will exclusively promote and sell the product in Japan.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_is_Biocon_share_price_today\"><\/span><strong>What is Biocon share price today?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Biocon share price closed at Rs 409.40 in the previous session (August 24, 2026), with an intraday range of Rs 409 to Rs 414.55.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_is_Pegfilgrastim_used_for\"><\/span><strong>What is Pegfilgrastim used for?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Pegfilgrastim is a biologic drug used in cancer supportive care to prevent infections (neutropenia) during chemotherapy by stimulating white blood cell production. Neulasta (Amgen) is the original branded Pegfilgrastim, and Biocon Biologics has developed a biosimilar version.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Who_will_sell_Biocons_Pegfilgrastim_in_Japan\"><\/span><strong>Who will sell Biocon&#8217;s Pegfilgrastim in Japan?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Sandoz K.K., the Japan subsidiary of Sandoz (the generics and biosimilars division of Novartis), will exclusively promote, sell, and distribute Biocon Biologics&#8217; Pegfilgrastim biosimilar in Japan. Global Regulatory Partners Japan serves as the Marketing Authorization Holder.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Why_is_Japan_MHLW_approval_significant_for_Biocon\"><\/span><strong>Why is Japan MHLW approval significant for Biocon?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Japan is the world&#8217;s third largest pharmaceutical market and has strict biosimilar regulatory standards. MHLW approval adds Japan to Biocon Biologics&#8217; Pegfilgrastim regulatory portfolio and opens access to Japanese chemotherapy patients through Sandoz K.K.&#8217;s established commercial network.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_is_Biocon_Biologics_biosimilar_portfolio\"><\/span><strong>What is Biocon Biologics&#8217; biosimilar portfolio?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Biocon Biologics has a global biosimilar portfolio spanning oncology support care (Pegfilgrastim, G-CSF), diabetes (insulin glargine, insulin aspart), immunology (Adalimumab, Trastuzumab), and ophthalmology (Bevacizumab). It is one of the world&#8217;s largest biosimilar companies by number of approved products across regulated markets.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Biocon Biologics received marketing approval from Japan MHLW for its Pegfilgrastim biosimilar (reference: Neulasta). Sandoz KK will exclusively promote and sell the product in Japan. Biocon share price Rs 409.40 in previous session. Japan is the world&#8217;s third largest pharma market.<\/p>\n","protected":false},"author":28,"featured_media":217694,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[24],"tags":[3802],"class_list":["post-217695","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-market","tag-news"],"metadata":{"rank_math_internal_links_processed":["1"],"_thumbnail_id":["217694"],"_edit_lock":["1787639060:28"],"_last_editor_used_jetpack":["block-editor"],"rank_math_primary_category":["24"],"rank_math_seo_score":["71"],"rank_math_title":["Biocon Share Price: Biocon Biologics Gets Japan MHLW Approval for Pegfilgrastim Biosimilar"],"rank_math_description":["Biocon share price in focus after Biocon Biologics receives marketing approval for Pegfilgrastim biosimilar from Japan MHLW. Sandoz KK to exclusively sell in Japan. Biocon CMP Rs 409.40."],"rank_math_focus_keyword":["Biocon share price"],"rank_math_robots":["a:2:{i:0;s:7:\"noindex\";i:1;s:8:\"nofollow\";}"],"_edit_last":["28"],"_ez-toc-disabled":[""],"_ez-toc-insert":[""],"_ez-toc-header-label":[""],"_ez-toc-alignment":["none"],"_ez-toc-heading-levels":["a:0:{}"],"_ez-toc-alttext":[""],"_ez-toc-visibility_hide_by_default":[""],"_ez-toc-hide_counter":[""],"_ez-toc-exclude":[""],"_ez-toc-position-specific":["before"],"stm_select_gm_zoom":[""],"stm_agenda":[""],"stm_host":[""],"stm_select_approved_denied":[""],"stm_multiselect_approved":[""],"stm_multiselect_denied":[""],"stm_date":[""],"stm_time":[""],"stm_timezone":[""],"stm_duration":[""],"stm_password":[""],"stm_waiting_room":[""],"stm_join_before_host":[""],"stm_host_join_start":[""],"stm_start_after_participants":[""],"stm_mute_participants":[""],"stm_enforce_login":[""],"stm_alternative_hosts":[""],"top_bar_custom_style":[""],"top_bar_bg":[""],"wc_top_bar_cart_custom_style":[""],"wc_top_bar_cart_color":[""],"wc_top_bar_cart_icon_color_hover":[""],"wc_top_bar_cart_counter_color":[""],"wc_top_bar_cart_counter_color_hover":[""],"wc_top_bar_cart_counter_bg":[""],"wc_top_bar_cart_counter_bg_hover":[""],"top_bar_wpml_switcher_custom_style":[""],"wpml_switcher_color":[""],"top_bar_wpml_switcher_bg":[""],"top_bar_wpml_switcher_bg_hover":[""],"top_bar_wpml_switcher_color_hover":[""],"top_bar_socials_custom_style":[""],"top_bar_socials_color":[""],"top_bar_socials_color_hover":[""],"top_bar_search_custom_style":[""],"top_bar_search_color":[""],"top_bar_search_icon_color_hover":[""],"top_bar_contact_info_style":[""],"top_bar_contact_info_color":[""],"top_bar_contact_info_link_color":[""],"top_bar_contact_info_link_color_hover":[""],"top_bar_contact_info_select_bg":[""],"top_bar_contact_info_select_color":[""],"top_bar_contact_info_select_drop_bg":[""],"top_bar_contact_info_select_items_bg":[""],"top_bar_contact_info_select_items_color":[""],"top_bar_contact_info_select_items_hover":[""],"header_inverse":["default"],"enable_header_transparent":["off"],"header_nav_custom_style":[""],"header_bg":[""],"header_shadow":[""],"wc_cart_custom_style":[""],"wc_cart_icon_color":[""],"wc_cart_icon_color_hover":[""],"wc_cart_counter_color":[""],"wc_cart_counter_color_hover":[""],"wc_cart_counter_bg":[""],"wc_cart_counter_bg_hover":[""],"header_wpml_switcher_custom_style":[""],"header_wpml_switcher_color":[""],"header_wpml_switcher_color_hover":[""],"header_wpml_switcher_bg":[""],"header_wpml_switcher_bg_hover":[""],"header_socials_custom_style":[""],"header_socials_color":[""],"header_socials_color_hover":[""],"header_search_custom_style":[""],"header_search_icon_color":[""],"header_search_icon_color_hover":[""],"header_contact_info_style":[""],"header_contact_info_color":[""],"header_contact_info_link_color":[""],"header_contact_info_link_color_hover":[""],"header_button_custom_style":[""],"header_button_color":[""],"header_button_color_hover":[""],"header_button_bg":[""],"header_button_bg_hover":[""],"header_nav_menu_customize":[""],"header_nav_menu_link_color":[""],"header_nav_menu_link_color_hover":[""],"header_nav_menu_link_color_active":[""],"header_nav_menu_link_arrow_color":[""],"header_nav_menu_link_arrow_color_hover":[""],"header_nav_menu_level_1_bg":[""],"header_nav_menu_level_1_link_color":[""],"header_nav_menu_level_1_link_color_hover":[""],"header_nav_menu_level_1_link_bg_hover":[""],"header_nav_menu_level_1_link_arrow_color":[""],"header_nav_menu_level_1_link_arrow_color_hover":[""],"header_nav_menu_level_2_bg":[""],"header_nav_menu_level_2_link_color":[""],"header_nav_menu_level_2_link_color_hover":[""],"header_nav_menu_level_2_link_bg_hover":[""],"header_mega_menu_bg":[""],"header_mega_menu_title_color":[""],"header_mega_menu_title_color_hover":[""],"header_mega_menu_description_color":[""],"header_mega_menu_description_link_color":[""],"header_mega_menu_description_link_color_hover":[""],"header_mega_menu_color":[""],"header_mega_menu_color_hover":[""],"header_mega_menu_border_color":[""],"header_mega_menu_icons_color":[""],"header_nav_menu_customize_end":[""],"hfe_enabled_notice":[""],"disable_title_box":["default"],"hfe_disabled":[""],"enable_transparent":["default"],"title_box_title_bg_color":[""],"title_box_bg_custom_image":["default"],"title_box_bg_image":[""],"title_box_bg_position":["default"],"metabox_title_box_bg_position_x":[""],"metabox_title_box_bg_position_y":[""],"metabox_title_box_bg_attachment":["default"],"title_box_bg_size":["default"],"metabox_title_box_bg_size_slider":[""],"title_box_bg_repeat":["default"],"disable_title":["default"],"title_box_title_color":[""],"title_box_title_line_color":[""],"disable_breadcrumbs":["default"],"metabox_title_box_breadcrumbs_color":[""],"metabox_title_box_links_color":[""],"metabox_title_box_links_color_hover":[""],"content_bg_transparent":[""],"show_popup_single":[""],"popups_single":[""],"popups_single_event":[""],"popup_single_event_open_delay":[""],"popup_single_event_showing_in":[""],"popup_single_event_date_from":[""],"popup_single_event_date_to":[""],"popup_single_event_time_from":[""],"popup_single_event_time_to":[""],"popup_single_animation":[""],"popup_single_responsive":[""],"separator_footer_copyright_border_t":[""],"name":[""],"email":[""],"phone":[""],"company":[""],"memberId":[""],"testimonial_position":[""],"testimonial_company":[""],"testimonial_bg_img":[""],"testimonial_video_url":[""],"popups_width":[""],"popups_height":[""],"popups_image_bg":[""],"popups_color_bg":[""],"popups_border_radius":[""],"popups_template":[""],"rank_math_analytic_object_id":["39811"]},"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/univest.in\/blogs-2\/wp-content\/uploads\/2026\/08\/biocon-share-price-japan-mhlw-pegfilgrastim-biosimilar-august-2026.png","_links":{"self":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/217695","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/users\/28"}],"replies":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/comments?post=217695"}],"version-history":[{"count":1,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/217695\/revisions"}],"predecessor-version":[{"id":218418,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/217695\/revisions\/218418"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media\/217694"}],"wp:attachment":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media?parent=217695"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/categories?post=217695"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/tags?post=217695"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}